CHUM Research Centre
Department of microbiology, infectiology and immunology, Université de Montréal
Canada Research Chair on Retroviral Entry
514-890-8000, ext. 35264
The patient who needs immediate assistance should not communicate directly with the researcher. Instead, they should call the doctor’s office or take other appropriate measures, such as going to the nearest emergency service.
HIV-1, envelope glycoproteins, gp120, gp41, fusion, CD4, CXCR4, CCR5, CD4-linked conformation, inhibitors.
Prevention of HIV transmission requires approaches that interrupt the early phase of infection with this retrovirus. An event of this phase is the entry of HIV into the target cells, which involves interactions between the envelope glycoproteins (gp120-gp41) and the CD4 receptor as well as the CCR5 or CXCR4 coreceptors. To interrupt viral entry, one must first understand the conformational and structural changes that allow HIV envelope glycoproteins to interact with these receptors to fuse with host cells.
My work is aimed at developing a new class of HIV entry inhibitors as well as designing better HIV immunogens that could pave the way for the development of effective HIV vaccines as well as better treatment options.
La course contre la montre pour la mise au point d’un vaccin (In French only)